Literature DB >> 12902798

Viral dynamics and their relations to baseline factors and longer term virologic responses in treatment-naive HIV-1-infected patients receiving abacavir in combination with HIV-1 protease inhibitors.

Hulin Wu1, John Mellors, Ping Ruan, Deborah McMahon, Dennis Kelleher, Michael M Lederman.   

Abstract

From a study of 71 HIV-1-infected patients receiving abacavir in combination with 1 of 5 different HIV-1 protease inhibitors (indinavir, ritonavir, saquinavir, nelfinavir, or amprenavir), we found that the baseline HIV-1 RNA levels were highly predictive of the viral decay rates. The baseline HIV-1 RNA levels were negatively correlated with the first phase viral decay rates (r = -0.77, P < 0.001) and positively correlated with the second phase viral decay rates (r = 0.68, P < 0.001). In addition, the first phase viral decay rate was positively correlated with CD4+ cell increases. No significant correlation was found between viral decay rates and longer term (24 weeks) virologic responses, and no difference in viral decay rates was found among the 5 study regimens. These data suggest that the potency of the 5 treatment regimens was similar and was not predictive of long-term virologic failure.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12902798     DOI: 10.1097/00126334-200308150-00002

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  3 in total

1.  Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection.

Authors:  Richard H Haubrich; Sharon A Riddler; Heather Ribaudo; Gregory Direnzo; Karin L Klingman; Kevin W Garren; David L Butcher; James F Rooney; Diane V Havlir; John W Mellors
Journal:  AIDS       Date:  2011-11-28       Impact factor: 4.177

2.  Optimal timing and duration of induction therapy for HIV-1 infection.

Authors:  Marcel E Curlin; Shyamala Iyer; John E Mittler
Journal:  PLoS Comput Biol       Date:  2007-07       Impact factor: 4.475

3.  Predicting virological decay in patients starting combination antiretroviral therapy.

Authors: 
Journal:  AIDS       Date:  2016-07-17       Impact factor: 4.177

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.